VThunter
a database for single-cell screening of virus target cells in animal kingdom
Lizard

Taxonomy:

Latin Name:

Tested tissues: Lung, Pallium,

Data set information
Project Date Technology Tissue Condition Cell PMID/DOI
Vthunter_0049 2021.04 10X Genomics Lung Normal 1702 Link
Vthunter_110082 2018.05 Drop-seq Pallium Normal 4187 Link
Virus Virus Name GeneTop 5 cell types expressing viral receptor ordered by expression proportion
Simian rotavirus A strain RRV
Pallium-No class : 93.33% ;
Pallium-pvExc4 : 89.80% ;
Pallium-pvExc1 : 88.14% ;
Pallium-pvExc2 : 87.27% ;
Pallium-pvInh2 : 85.88% ;
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Secretory cells : 54.76% ;
Lung-Ciliated cells : 40.98% ;
Lung-Endothelial cells : 18.13% ;
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Severe acute respiratory syndrome coronavirus 2
Lung-ATI : 85.71% ;
Lung-Fibroblasts : 73.26% ;
Lung-ATII : 59.30% ;
Lung-Secretory cells : 57.14% ;
Lung-Endothelial cells : 52.85% ;
Lung-Secretory cells : 50.00% ;
Lung-ATII : 41.40% ;
Lung-Macrophages : 28.57% ;
Lung-Ciliated cells : 25.69% ;
Lung-Endothelial cells : 20.21% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Rabies lyssavirus
Pallium-pvInh2 : 76.47% ;
Pallium-pvExc4 : 76.02% ;
Pallium-No class : 73.33% ;
Pallium-pvInh1 : 64.33% ;
Pallium-pvExc3 : 55.56% ;
Pallium-pvExc3 : 16.56% ;
Hepacivirus C
Lung-Secretory cells : 76.19% ;
Lung-Ciliated cells : 63.69% ;
Lung-ATII : 43.33% ;
Lung-ATI : 42.86% ;
Lung-Fibroblasts : 30.48% ;
Lung-ATI : 63.49% ;
Lung-Secretory cells : 54.76% ;
Lung-ATII : 45.09% ;
Pallium-pvOlig : 35.57% ;
Lung-Ciliated cells : 30.15% ;
Pallium-pvInh2 : 50.59% ;
Pallium-pvEG : 46.15% ;
Pallium-pvExc1 : 45.76% ;
Pallium-pvExc3 : 41.30% ;
Pallium-No class : 40.00% ;
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Lung-Secretory cells : 50.00% ;
Lung-ATII : 41.40% ;
Lung-Macrophages : 28.57% ;
Lung-Ciliated cells : 25.69% ;
Lung-Endothelial cells : 20.21% ;
Lung-Secretory cells : 42.86% ;
Lung-Ciliated cells : 41.83% ;
Lung-ATI : 34.92% ;
Lung-ATII : 31.05% ;
Lung-Fibroblasts : 25.13% ;
Lung-Endothelial cells : 31.61% ;
Lung-Secretory cells : 26.19% ;
Lung-Ciliated cells : 21.44% ;
Pallium-pvVend : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Pallium-pvMG : 17.27% ;
Pallium-pvMur : 16.67% ;
Lassa mammarenavirus
Lung-ATI : 76.19% ;
Lung-Secretory cells : 52.38% ;
Pallium-pvVend : 50.00% ;
Lung-Fibroblasts : 49.73% ;
Pallium-pvEG : 44.81% ;
Pallium-pvEG : 46.54% ;
Pallium-pvOlig : 41.20% ;
Pallium-pvExc4 : 37.76% ;
Pallium-pvExc3 : 31.03% ;
Pallium-No class : 26.67% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Lung-Secretory cells : 16.67% ;
Andes orthohantavirus
Lung-Secretory cells : 76.19% ;
Lung-ATII : 47.89% ;
Lung-Endothelial cells : 45.08% ;
Lung-Ciliated cells : 32.91% ;
Lung-ATI : 30.16% ;
Oliveros mammarenavirus
Lung-ATI : 76.19% ;
Lung-Secretory cells : 52.38% ;
Pallium-pvVend : 50.00% ;
Lung-Fibroblasts : 49.73% ;
Pallium-pvEG : 44.81% ;
Human betaherpesvirus 5
Lung-Secretory cells : 76.19% ;
Lung-Ciliated cells : 63.69% ;
Lung-ATII : 43.33% ;
Lung-ATI : 42.86% ;
Lung-Fibroblasts : 30.48% ;
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Pallium-pvMG : 17.27% ;
Lymphocytic choriomeningitis mammarenavirus
Lung-ATI : 76.19% ;
Lung-Secretory cells : 52.38% ;
Pallium-pvVend : 50.00% ;
Lung-Fibroblasts : 49.73% ;
Pallium-pvEG : 44.81% ;
Pallium-pvEG : 46.54% ;
Pallium-pvOlig : 41.20% ;
Pallium-pvExc4 : 37.76% ;
Pallium-pvExc3 : 31.03% ;
Pallium-No class : 26.67% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Sin Nombre orthohantavirus
Lung-Secretory cells : 76.19% ;
Lung-ATII : 47.89% ;
Lung-Endothelial cells : 45.08% ;
Lung-Ciliated cells : 32.91% ;
Lung-ATI : 30.16% ;
Influenza A virus
Lung-Secretory cells : 76.19% ;
Lung-Ciliated cells : 63.69% ;
Lung-ATII : 43.33% ;
Lung-ATI : 42.86% ;
Lung-Fibroblasts : 30.48% ;
Pallium-pvExc4 : 68.37% ;
Pallium-No class : 60.00% ;
Pallium-pvExc3 : 57.02% ;
Pallium-pvInh2 : 48.24% ;
Pallium-pvExc2 : 47.88% ;
Pallium-pvVend : 66.67% ;
Lung-ATI : 53.97% ;
Lung-Secretory cells : 47.62% ;
Lung-Fibroblasts : 39.04% ;
Pallium-pvMur : 33.33% ;
Lung-ATI : 42.86% ;
Lung-Secretory cells : 33.33% ;
Lung-ATII : 31.40% ;
Lung-Ciliated cells : 23.78% ;
Pallium-pvVend : 22.22% ;
Pallium-pvMG : 17.27% ;
Latino mammarenavirus
Lung-ATI : 76.19% ;
Lung-Secretory cells : 52.38% ;
Pallium-pvVend : 50.00% ;
Lung-Fibroblasts : 49.73% ;
Pallium-pvEG : 44.81% ;
Enterovirus A71
Pallium-pvOlig : 73.32% ;
Pallium-pvEG : 35.00% ;
Pallium-No class : 33.33% ;
Pallium-pvInh2 : 29.41% ;
Pallium-pvExc4 : 25.00% ;
Coxsackievirus A16
Pallium-pvOlig : 73.32% ;
Pallium-pvEG : 35.00% ;
Pallium-No class : 33.33% ;
Pallium-pvInh2 : 29.41% ;
Pallium-pvExc4 : 25.00% ;
Echovirus E1
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Secretory cells : 54.76% ;
Lung-Ciliated cells : 40.98% ;
Lung-Endothelial cells : 18.13% ;
Echovirus E8
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Secretory cells : 54.76% ;
Lung-Ciliated cells : 40.98% ;
Lung-Endothelial cells : 18.13% ;
Equid alphaherpesvirus 1
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Macrophages : 25.40% ;
Lung-T cells : 22.92% ;
Pallium-pvMG : 19.06% ;
Pallium-pvVend : 16.67% ;
Human parvovirus B19
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Endothelial cells : 54.92% ;
Lung-Secretory cells : 35.71% ;
Lung-Ciliated cells : 22.72% ;
Lung-Smooth muscle cells : 21.88% ;
Lung-Macrophages : 19.05% ;
Foot-and-mouth disease virus
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-ATI : 71.43% ;
Lung-ATII : 56.14% ;
Lung-Secretory cells : 50.00% ;
Lung-Ciliated cells : 32.91% ;
Lung-Macrophages : 20.63% ;
Lung-Endothelial cells : 54.92% ;
Lung-Secretory cells : 35.71% ;
Lung-Ciliated cells : 22.72% ;
Lung-Smooth muscle cells : 21.88% ;
Lung-Macrophages : 19.05% ;
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Lung-Secretory cells : 16.67% ;
Mammalian orthoreovirus
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Pallium-pvExc3 : 45.28% ;
Pallium-pvExc1 : 30.51% ;
Pallium-pvOPC : 27.89% ;
Pallium-No class : 26.67% ;
Pallium-pvExc4 : 18.37% ;
Human metapneumovirus
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Endothelial cells : 54.92% ;
Lung-Secretory cells : 35.71% ;
Lung-Ciliated cells : 22.72% ;
Lung-Smooth muscle cells : 21.88% ;
Lung-Macrophages : 19.05% ;
Human gammaherpesvirus 4
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Adeno-associated virus - 2
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Endothelial cells : 54.92% ;
Lung-Secretory cells : 35.71% ;
Lung-Ciliated cells : 22.72% ;
Lung-Smooth muscle cells : 21.88% ;
Lung-Macrophages : 19.05% ;
Lung-Secretory cells : 54.76% ;
Pallium-pvExc4 : 24.49% ;
Pallium-No class : 20.00% ;
Pallium-pvInh2 : 17.65% ;
Lung-ATII : 17.02% ;
Human rotavirus strain WA
Pallium-pvVend : 72.22% ;
Pallium-pvMur : 71.43% ;
Pallium-pvEG : 47.88% ;
Lung-Secretory cells : 42.86% ;
Pallium-pvOPC : 39.70% ;
Lung-Secretory cells : 54.76% ;
Lung-Ciliated cells : 40.98% ;
Lung-Endothelial cells : 18.13% ;
Human alphaherpesvirus 1
Lung-ATI : 71.43% ;
Lung-ATII : 56.14% ;
Lung-Secretory cells : 50.00% ;
Lung-Ciliated cells : 32.91% ;
Lung-Macrophages : 20.63% ;
Lung-Secretory cells : 69.05% ;
Lung-ATI : 57.14% ;
Lung-Ciliated cells : 50.32% ;
Lung-ATII : 48.25% ;
Lung-Fibroblasts : 44.92% ;
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Lung-Secretory cells : 16.67% ;
Human alphaherpesvirus 2
Lung-Secretory cells : 69.05% ;
Lung-ATI : 57.14% ;
Lung-Ciliated cells : 50.32% ;
Lung-ATII : 48.25% ;
Lung-Fibroblasts : 44.92% ;
Suid alphaherpesvirus 1
Lung-Secretory cells : 69.05% ;
Lung-ATI : 57.14% ;
Lung-Ciliated cells : 50.32% ;
Lung-ATII : 48.25% ;
Lung-Fibroblasts : 44.92% ;
Human rhinovirus A2
Lung-ATI : 63.49% ;
Lung-Secretory cells : 54.76% ;
Lung-ATII : 45.09% ;
Pallium-pvOlig : 35.57% ;
Lung-Ciliated cells : 30.15% ;
Vesicular stomatitis virus
Lung-ATI : 63.49% ;
Lung-Secretory cells : 54.76% ;
Lung-ATII : 45.09% ;
Pallium-pvOlig : 35.57% ;
Lung-Ciliated cells : 30.15% ;
Lung-ATI : 42.86% ;
Lung-Secretory cells : 33.33% ;
Lung-ATII : 31.40% ;
Lung-Ciliated cells : 23.78% ;
Pallium-pvVend : 22.22% ;
Gibbon ape leukemia virus
Lung-Secretory cells : 61.90% ;
Pallium-pvInh2 : 37.65% ;
Lung-Endothelial cells : 37.31% ;
Lung-ATII : 36.32% ;
Lung-Fibroblasts : 33.16% ;
Pallium-pvVend : 33.33% ;
Pallium-pvExc4 : 31.12% ;
Pallium-No class : 26.67% ;
Pallium-pvInh2 : 25.88% ;
Pallium-pvInh1 : 24.20% ;
Amphotropic murine leukemia virus
Lung-Secretory cells : 61.90% ;
Pallium-pvInh2 : 37.65% ;
Lung-Endothelial cells : 37.31% ;
Lung-ATII : 36.32% ;
Lung-Fibroblasts : 33.16% ;
Feline leukemia virus strain B/lambda-B1
Lung-Secretory cells : 61.90% ;
Pallium-pvInh2 : 37.65% ;
Lung-Endothelial cells : 37.31% ;
Lung-ATII : 36.32% ;
Lung-Fibroblasts : 33.16% ;
Pallium-pvVend : 33.33% ;
Pallium-pvExc4 : 31.12% ;
Pallium-No class : 26.67% ;
Pallium-pvInh2 : 25.88% ;
Pallium-pvInh1 : 24.20% ;
Human papillomavirus type 16
Lung-ATI : 50.79% ;
Lung-Fibroblasts : 47.06% ;
Lung-Secretory cells : 40.48% ;
Pallium-pvEG : 29.04% ;
Lung-Ciliated cells : 25.69% ;
Lung-Secretory cells : 40.48% ;
Pallium-pvOlig : 28.68% ;
Lung-Fibroblasts : 28.34% ;
Lung-ATI : 26.98% ;
Lung-Endothelial cells : 23.32% ;
Guanarito mammarenavirus
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Canine parvovirus
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Lung-ATII : 15.26% ;
Machupo mammarenavirus
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Lung-ATII : 15.26% ;
Feline panleukopenia virus
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Lung-ATII : 15.26% ;
Argentinian mammarenavirus
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Mouse mammary tumor virus
Pallium-pvVend : 50.00% ;
Pallium-No class : 40.00% ;
Lung-Secretory cells : 33.33% ;
Lung-B cells : 21.21% ;
Bovine leukemia virus
Pallium-pvInh2 : 47.06% ;
Pallium-pvExc4 : 42.86% ;
Pallium-pvExc1 : 37.29% ;
Pallium-No class : 33.33% ;
Pallium-pvInh1 : 32.48% ;
Zika virus
Pallium-pvEG : 46.54% ;
Pallium-pvOlig : 41.20% ;
Pallium-pvExc4 : 37.76% ;
Pallium-pvExc3 : 31.03% ;
Pallium-No class : 26.67% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Ebola virus
Pallium-pvEG : 46.54% ;
Pallium-pvOlig : 41.20% ;
Pallium-pvExc4 : 37.76% ;
Pallium-pvExc3 : 31.03% ;
Pallium-No class : 26.67% ;
Pallium-pvOlig : 39.02% ;
Lung-Secretory cells : 33.33% ;
Lung-Ciliated cells : 23.57% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Pallium-pvMG : 17.27% ;
Lung-Endothelial cells : 17.10% ;
Dengue virus
Pallium-pvEG : 46.54% ;
Pallium-pvOlig : 41.20% ;
Pallium-pvExc4 : 37.76% ;
Pallium-pvExc3 : 31.03% ;
Pallium-No class : 26.67% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Pallium-pvMur : 16.67% ;
Marburg marburgvirus
Pallium-pvEG : 46.54% ;
Pallium-pvOlig : 41.20% ;
Pallium-pvExc4 : 37.76% ;
Pallium-pvExc3 : 31.03% ;
Pallium-No class : 26.67% ;
Lung-Fibroblasts : 20.32% ;
Pallium-pvMur : 16.67% ;
Lung-Smooth muscle cells : 15.62% ;
Pallium-pvMG : 17.27% ;
Lung-Endothelial cells : 17.10% ;
Chikungunya virus
Pallium-pvExc4 : 46.43% ;
Pallium-pvInh2 : 35.29% ;
Pallium-pvInh1 : 28.66% ;
Pallium-pvExc3 : 28.30% ;
Pallium-No class : 26.67% ;
Lung-Fibroblasts : 31.55% ;
Feline leukemia virus strain C/FA27
Pallium-pvVend : 44.44% ;
Pallium-pvExc4 : 16.33% ;
Porcine reproductive and respiratory syndrome virus
Lung-Secretory cells : 40.48% ;
Pallium-pvOlig : 28.68% ;
Lung-Fibroblasts : 28.34% ;
Lung-ATI : 26.98% ;
Lung-Endothelial cells : 23.32% ;
Hendra henipavirus
Lung-Endothelial cells : 40.41% ;
Lung-Secretory cells : 33.33% ;
Nipah henipavirus
Lung-Endothelial cells : 40.41% ;
Lung-Secretory cells : 33.33% ;
Jaagsiekte sheep retrovirus
Pallium-pvVend : 38.89% ;
Xenotropic murine leukemia virus
Pallium-pvNPC : 33.83% ;
Pallium-No class : 33.33% ;
Pallium-pvExc4 : 26.53% ;
Lung-Secretory cells : 26.19% ;
Lung-ATI : 25.40% ;
Polytropic murine leukemia virus
Pallium-pvNPC : 33.83% ;
Pallium-No class : 33.33% ;
Pallium-pvExc4 : 26.53% ;
Lung-Secretory cells : 26.19% ;
Lung-ATI : 25.40% ;
Simian type D retrovirus -Tsukuba
Lung-Secretory cells : 33.33% ;
Lung-Ciliated cells : 19.11% ;
Feline endogenous virus RD114
Lung-Secretory cells : 33.33% ;
Lung-Ciliated cells : 19.11% ;
Simian sarcoma-associated virus
Pallium-pvVend : 33.33% ;
Pallium-pvExc4 : 31.12% ;
Pallium-No class : 26.67% ;
Pallium-pvInh2 : 25.88% ;
Pallium-pvInh1 : 24.20% ;
Baboon endogenous virus strain M7
Lung-Secretory cells : 33.33% ;
Lung-Ciliated cells : 19.11% ;
Human mastadenovirus C
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Lung-ATI : 19.05% ;
Lung-Secretory cells : 19.05% ;
Pallium-pvNPC : 18.80% ;
Human gammaherpesvirus 8
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
West Nile virus
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Pallium-pvMG : 17.27% ;
Coxsackievirus A9
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Lung-Secretory cells : 16.67% ;
Human parechovirus 1
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Coxsackievirus B1
Pallium-pvMG : 32.37% ;
Lung-Secretory cells : 26.19% ;
Pallium-pvEG : 23.85% ;
Lung-Fibroblasts : 21.93% ;
Pallium-No class : 20.00% ;
Pallium-pvNPC : 18.80% ;
Lung-Secretory cells : 16.67% ;
Onyong-nyong virus
Lung-Fibroblasts : 31.55% ;
Ross River virus
Lung-Fibroblasts : 31.55% ;
Mayaro virus
Lung-Fibroblasts : 31.55% ;
Ecotropic murine leukemia virus
Lung-Secretory cells : 28.57% ;
Pallium-pvVend : 27.78% ;
Pallium-pvExc4 : 23.98% ;
Pallium-pvExc1 : 18.64% ;
Encephalomyocarditis virus
Pallium-pvVend : 27.78% ;
Pallium-No class : 20.00% ;
Pallium-pvExc1 : 16.95% ;
Human immunodeficiency virus 1
Pallium-pvEG : 26.15% ;
Pallium-pvVend : 16.67% ;
Pallium-pvMG : 17.27% ;
Feline immunodeficiency virus
Pallium-pvEG : 26.15% ;
Pallium-pvVend : 16.67% ;
Human immunodeficiency virus 2
Pallium-pvEG : 26.15% ;
Pallium-pvVend : 16.67% ;
Hepatitis delta virus
Lung-ATI : 20.63% ;
Coxsackievirus B2
Pallium-pvNPC : 18.80% ;
Coxsackievirus B3
Pallium-pvNPC : 18.80% ;
Coxsackievirus B4
Pallium-pvNPC : 18.80% ;
Coxsackievirus B5
Pallium-pvNPC : 18.80% ;
Human mastadenovirus E
Pallium-pvNPC : 18.80% ;
Human mastadenovirus F
Pallium-pvNPC : 18.80% ;
Human mastadenovirus D
Pallium-pvNPC : 18.80% ;
Human mastadenovirus A
Pallium-pvNPC : 18.80% ;
Coxsackievirus B6
Pallium-pvNPC : 18.80% ;
Respiratory syncytial virus
Pallium-pvMG : 17.27% ;
SARS coronavirus
Pallium-pvMG : 17.27% ;
Human coronavirus 229E
Pallium-pvMG : 17.27% ;
Japanese encephalitis virus
Pallium-pvMG : 17.27% ;
Varicella Zoster Virus
Pallium-pvExc4 : 15.31% ;
Human alphaherpesvirus 3
Pallium-pvExc4 : 15.31% ;

Contact Us

E-mail: chendongsheng@genomics.cn

Address: Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China

Copyright © VThunter 2020-2021 ShenZhen, Guangdong province, China